Shares of genomic testing pioneer Veracyte (NASDAQ:VCYT) are up nearly 30% in the past year and 48% in the past six months.
The company appears to finally be receiving increasing coverage as Wall Street warms up to the story, with a slew of good news to start 2017. They offer three commercial products with a combined $2 billion market opportunity, projected to expand to nearly $3 billion by 2020.
